EGFR and non-small cell lung carcinoma: The phase two EVAN trial randomized 102 patients with radically resected stage IIIA EGFR mutant NSCLC to receive adjuvant erlotinib for up to two years vs. cisplatin-vinorelbine chemotherapy.